Demonstrates the impact and synergy of BioGenerator’s pre-investment programs to use start- up coaching, strategy formation and resources to drive large quantities of non-dilutive funding as an attractant for Angel and, ultimately, VC investors.
KaloCyte Inc. is developing an artificial red-blood cell for use as a resuscitation agent in environments where whole-blood supplementation is unavailable or un-desirable. The company has been enormously effective in winning substantial dilutive and non-dilutive funding and advancing its product ErythroMerTM towards commercialization.
BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling the company to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and funding,
BioGenerator Grants paid 3rd party expertise to independently evaluate the company’s IP. The G2B program recruited the necessary expertise to craft two highly effective grant applications totaling $5M. One of these is with an important potential customer (US DOD) and a separate grant initiative with BARDA.
BioGenerator Senior Director Harry Arader played the role of acting start-up CEO, recruiting most company consultants and full-time employees and at least one board member. He has also led the Company’s first dilutive fund raise. BioGenerator EIR Elaine Haynes now serves as the company’s CEO. BioGenerator Ventures invested in the company's seed round.